At a glance
- Originator Taisho Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 17 Jan 2000 A preclinical study has been added to the Hyperlipidaemia pharmacodynamics section
- 02 Jun 1998 Phase-I clinical trials for Hyperlipidaemia in Japan (Unknown route)
- 12 Sep 1997 A study in stroke-prone spontaneously hypertensive rats has been added to the Hyperlipidaemia pharmacodynamics section